Clostridioides difficile infection (CDI) is one of the major issues in nosocomial infections.
This bacterium is constantly evolving and poses complex challenges for clinicians, often …

Background Several new treatments for Clostridium difficile infections have been
investigated. We aimed to compare and rank treatments for non-multiply recurrent infections …

Background Clostridium difficile is the most common cause of infectious diarrhea in
hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and …

Background Fidaxomicin (FDX) has received considerable attention as a novel therapeutic
alternative agent to vancomycin (VCM) for Clostridioides difficile infection (CDI). However …

Abstract Recurrent Clostridioides (formerly Clostridium) difficile infection (rCDI) is common,
and patients who have had one recurrence are more likely to have multiple recurrences …

Background Current practice guidelines favour fidaxomicin over vancomycin and exclude
metronidazole from the recommended standard regimen for Clostridioides difficile infection …

In recently updated international guidelines, fidaxomicin is preferentially recommended as
first-line treatment over vancomycin both for the first episode of CDI and for rCDI, based on …

Background Limited data currently exist on the incidence of Clostridioides difficile infection
(CDI) in Saudi Arabia. Compliance with CDI treatment guidelines is prudent for proper …

The pathogenesis of Clostridioides difficile infection (CDI) has largely been attributed to the
action of two major toxins–A and B. An enhanced systemic humoral immune response …

Background The fully human monoclonal antibody bezlotoxumab binds Clostridioides
(Clostridium) difficile toxin B and reduces recurrence rates in patients with C. difficile …